{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Cellectar Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"CLRB"},"Address":{"label":"Address","value":"100 CAMPUS DRIVE, FLORHAM PARK, New Jersey, 07932, United States"},"Phone":{"label":"Phone","value":"+1 608 441-8120"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells."},"CompanyUrl":{"label":"Company Url","value":"https://www.cellectar.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andrei Shustov","title":"Senior Vice President-Medical"},{"name":"James V. Caruso","title":"President, Chief Executive Officer & Director"},{"name":"Jarrod Longcor","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}